Turning the backbone into an ankylosed concrete-like structure: Case report.

RATIONALE: Progressive restriction of the spinal bio-mechanics is not-uncommon deformity encountered in spine clinics. Congenital spinal fusion as seen in Klippel-Feil-anomaly, progressive non-infectious anterior vertebral fusion, and progressive spinal hyperostosis secondary to ossification of the anterior longitudinal spinal ligament are well delineated and recognized. PATIENT CONCERNS: A 24-year-old girl has history of osteoporosis since her early childhood, associated with multiple axial and appendicular fractures and scoliosis. Recently she presented with episodes of severe back pain, spinal rigidity/stiffness with total loss of spine biomechanics. DIAGNOSES: She was provisionally diagnosed as having osteogenesis imperfecta and was investigated for COL1A1/A2 mutations which have been proven to be negative. Autosomal recessive type of osteogenesis imperfecta was proposed as well, no mutations have been encountered. A homozygous for CTSA gene mutation, the gene associated with Galactosialidosis was identified via whole exome sequencing (Next-Generation Sequencing projects) has been identified. INTERVENTIONS: Early in her life she had a history of frequent fractures of the long bones since she was 4 years which was followed by vertebral fractures at the age of 12 years. She manifested lower serum 25OH-D levels and were associated with lower LS-aBMD Z-scores with higher urinary bone turnover indexes (urinary NTX/Cr). OUTCOMES: Lysosomal storage diseases (LSD) have a strong correlation with the development of osteoporosis. LSD causes skeletal abnormalities results from a lack of skeletal remodeling and ossification abnormalities owing to abnormal deposition of GAGs (impaired degradation of glycosaminoglycans ) in bone and cartilage. 3D reconstruction CT scan of the spine showed diffuse hyperostosis of almost the entire spine (begins at the level of T4- extending downwards to involve the whole thoraco-lumbar and upper part of the sacrum) with total diffuse fusion of the pedicles, the transverse and articular processes, the laminae and the spinous processes. LESSONS: This is the first clinical report of adult patient with a history of osteoporosis and fractures with the late diagnosis of Galactosialidosis. Osteogenesis imperfecta (autosomal dominant and recessive) were the first given diagnoses which proven negative. The pathophysiology of the spine ankylosis in our current patient and its correlation with LSD, antiresorptive medications, vitamin D3 and supplemental calcium is not fully understood. Therefore, further studies are needed to elucidate this sort of correlation.

Intoxicação por Solanum paniculatum (Solanaceae) em bovinos / Poisoning by Solanum paniculatum (Solanaceae) in cattle

Surtos de uma doença neurológica com sinais cerebelares ocorreram em três fazendas da região Agreste do Estado de Pernambuco. A morbidade foi de 3 a 25%, a mortalidade variou de 0 a 20% e a letalidade foi de 0 a 60%. Uma planta que predominava nos pastos das fazendas foi identificada como Solanum paniculatum. Os sinais clínicos apresentados foram de crises periódicas caracterizadas por incoordenação, extensão da cabeça e pescoço, ataxia, hipermetria, tremores de intenção, nistagmo e quedas. As crises eram induzidas pelo teste de levantar a cabeça ou quando os animais eram assustados ou quando aplicado o teste de levantar a cabeça. Alguns animais apresentaram sinais permanentes com alterações posturais, tremores de intenção, andar cambaleante com os membros em abdução e perda progressiva de peso. De dois bovinos que foram necropsiados, um apresentava diminuição de tamanho do cerebelo com marcada atrofia da substância cinzenta. Histologicamente, um dos bovinos apresentou vacuolização fina do pericário das células de Purkinje do cerebelo com marginalização do núcleo. Em algumas áreas havia perda de neurônios de Purkinje com proliferação de astrócitos de Bergmann. Degeneração do tipo Walleriana, com esferoides axonais e vacúolos, alguns contendo macrófagos, foi observada na camada granular do cerebelo, substância branca cerebelar e medula cerebelar. Neurônios vacuolizados e esferóides axonais foram observados também no núcleo gracilis. Em outro bovino com sinais permanentes, que permaneceu por aproximadamente 10 meses sem ter acesso a S. paniculatum, observou-se ausência quase total de células de Purkinje. Havia severa depleção das camadas granular e molecular que se encontravam marcadamente diminuídas de espessura e com rarefação do neurópilo e menor número de células. Considerando que se desconhece o princípio ativo de S. paniculatum e que a planta é largamente utilizada como planta medicinal é necessário alertar para os riscos de intoxicação em humanos.

Outbreaks of a disease of the nervous system are reported in cattle in three farms in the Agreste region of the state of Pernambuco. Morbidity, mortality and fatality rates varied from 3 to 25%, 0 to 20% and 0 to 60%, respectively. A weed found in large amounts in the pastures was identified as Solanum paniculatum. Clinical signs were characterized by transitory, periodic attacks with loss of balance, incoordinated gait, neck and head extension, hypermetria, intention tremors, nystagmus, and falls. The attacks were induced when the animals were disturbed or by the application of the head raising test. Two cows showed permanent signs including ataxia, abnormal posture, staggering gait with limbs in abduction, intention tremors, hypermetria, and progressive weight loss. Histological lesions in one cow were fine vacuolation of the cerebellar Purkinje neurons with marginalization of the nucleus. Loss of Purkinje neurons with proliferation of Bergmann astrocytes and Wallerian degeneration with axonal spheroids in the granular layer and cerebellar white matter were also observed. Neuronal vacuolation and axonal spheroids were observed in the gracillis nucleus. In one cow that stayed for approximately 10 months in an area free of S. paniculatum with permanent signs, there was a severe depletion of Purkinje neurons in the cerebellum. The granular and molecular layers were reduced and depleted of cells. Considering that the toxic compound of S. paniculatum is unknown, and that the plant is largely used as a medical plant, it is necessary to take into account the risk of human poisoning.

Substrate reduction therapy.

UNLABELLED: The therapeutic options for lysosomal storage diseases (LSDs) have expanded greatly over the past decade, although for many disorders there is still no effective treatment. Given that the majority of LSDs involve pathological changes in both the brain and peripheral tissues, effective treatment of central nervous system (CNS) and peripheral manifestations still remains a considerable technical challenge. Type 1 Gaucher disease has two approved treatment modalities - enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) - which have unique, independent and potentially complementary mechanisms of action. The availability of these two therapies has greatly increased the options for the effective clinical management of type 1 Gaucher disease. ERT involves the intravenous administration of fully functional enzyme that is taken up by cells and delivered to the lysosome, where it can compensate for the underlying enzyme deficiency. SRT uses an orally available, small molecule drug that inhibits the first committed step in glycosphingolipid biosynthesis. The aim is to reduce the rate of biosynthesis of glycosphingolipids to offset the catabolic defect, restoring the balance between the rate of biosynthesis and the rate of catabolism. SRT also has the potential to treat LSDs with CNS pathology, as the drug in clinical use (miglustat, Zavesca; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland) crosses the blood-brain barrier. In this review, the current status of SRT for the treatment of Gaucher disease and other LSDs will be discussed, based upon preclinical and clinical studies. CONCLUSION: SRT is an oral alternative treatment option for patients with type 1 Gaucher disease unwilling or unable to receive ERT. With the recent reports of clinical improvement/stabilization of CNS manifestations following SRT in patients with Niemann-Pick disease type C, miglustat may also have a role to play in the management of patients with glycosphingolipid storage in the brain. Furthermore, as SRT synergises with other therapeutic modalities, it may also prove to be a key component of combination therapies in the future.